The potential benefits of ProAxsis’ novel ProteaseTag® Active Proteinase 3 Immunoassay will be discussed at the Winter meeting of the British Thoracic …
Type and hit ENTER
David Ribeiro
November 26, 2018
ProAxsis Limited (www.proaxsis.com), the Belfast-based company focused on developing new assays for the measurement of active protease biomarkers of disease, today announces …
September 20, 2018
ProAxsis will today be presenting new data on its highly novel active neutrophil elastase (NE) point-of-care test, NEATstik®, at the European …
September 18, 2018
ProAxsis Limited (www.proaxsis.com), the Belfast-based company focused on developing new assays for the measurement of active protease biomarkers of disease, today announces …
August 2, 2018
ProAxsis will be presenting three abstracts at the COPD 11 Conference, which takes place between June 20th-21st 2018 in Birmingham, UK. …
June 18, 2018
ProAxsis Limited has been declared as the “Innovative Business of the Year” at the Business Eye First Trust Awards (BEFTAs) for …
June 4, 2018
ProAxsis Limited has received an Invest NI Grant for Research and Development, supporting the company to develop new products using its innovative …
June 1, 2018
ProAxsis confirms that new data on its ProteaseTag® technology will be presented at the American Thoracic Society Conference, which takes place …
May 2, 2018
ProAxsis is proud to be collaborating with Dr. Gunnar Schroeder and Prof. Cliff Taggart from the School of Medicine, Dentistry and …
March 6, 2018
Following on from the commercialisation update provided in November, ProAxsis is pleased to report the first sale of NEATstik®, the company’s novel …
February 15, 2018
ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland
tel +44 (0)28 9073 0444
email info@proaxsis.com
Copyright © 2016-2018 - ProAxsis - All rights reserved.
David Ribeiro, Author at ProAxsis